Provectus Biopharmaceuticals, Inc.
PVCT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$21.01M
Close$
$-0.01
118.4% downside
Current Fair Value
118.4% downsideOvervalued by 118.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $21.01 Million |
|---|---|
| Enterprise Value | $24.60 Million |
| Earnings per Share | $-0.01 |
| Beta | 0.9 |
| Outstanding Shares | 420,279,879 |
Return
| Return on Equity | 75.54% |
|---|---|
| Return on Assets | -322.32% |
| Return on Invested Capital | 16.42% |
Valuation & Multiples
| P/E Ratio | -4.42 |
|---|---|
| PEG | 9.42 |
| Price to Sales | - |
| Price to Book Ratio | -0.05 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -24.03 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | -0.75 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 0.02% |
|---|---|
| Total Invested | $8,969▼ 13.55% |
| Investors Holding | 3▼ 2.00% |
About Provectus Biopharmaceuticals, Inc.
6 employees
CEO: Mr. Dominic Rodrigues C.F.A.
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult soli...